Another tick in the box in readiness for the US market.
Although the Company is unable to quantify the revenue impact at this stage, the new distribution agreement is considered to be strategically material as it seeks to grow its footprint rapidly in the US market once the Company has FDA clearance which is targeted for Q1 2024
Fingers crossed that all goes according to plan here. If so, calendar year 2024 will be big. And my target of 2025 objectives should be met easily. All this does not even touch on the infant app yet. PCK will be a monster company in time to come.
Pain is everywhere and everyone wants it gone. And who do you call? PAINCHEK
p.s. Good to hear that the Canadian market has started implementation.
Ann: Ethos Laboratories Distribution Agreement, page-3
Add PCK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.001(3.23%) |
Mkt cap ! $50.75M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.3¢ | 3.1¢ | $26.23K | 833.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 10300417 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 65057 | 1 |
View Market Depth
| Last trade - 14.41pm 10/10/2024 (20 minute delay) ? |
| PCK (ASX) Chart |